Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.

Paquette MA, Foley K, Brudney EG, Meshul CK, Johnson SW, Berger SP.

Psychopharmacology (Berl). 2009 Jul;204(4):743-54. doi: 10.1007/s00213-009-1505-8. Epub 2009 Mar 13. Erratum in: Psychopharmacology (Berl). 2009 May;204(1):185-7.

2.

The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.

Bhide N, Lindenbach D, Surrena MA, Goldenberg AA, Bishop C, Berger SP, Paquette MA.

Psychopharmacology (Berl). 2013 Jun;227(3):533-44. doi: 10.1007/s00213-013-3001-4. Epub 2013 Feb 7.

3.

The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.

Eskow KL, Gupta V, Alam S, Park JY, Bishop C.

Pharmacol Biochem Behav. 2007 Aug-Sep;87(3):306-14. Epub 2007 May 13.

PMID:
17553556
4.

Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.

Iderberg H, McCreary AC, Varney MA, Cenci MA, Newman-Tancredi A.

Neuropharmacology. 2015 Jun;93:52-67. doi: 10.1016/j.neuropharm.2015.01.012. Epub 2015 Jan 31.

PMID:
25645393
5.

Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.

Pinna A, Ko WK, Costa G, Tronci E, Fidalgo C, Simola N, Li Q, Tabrizi MA, Bezard E, Carta M, Morelli M.

Mov Disord. 2016 Apr;31(4):501-11. doi: 10.1002/mds.26475. Epub 2016 Feb 12.

PMID:
26871939
6.

NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.

Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortère R, Cenci MA, Newman-Tancredi A.

Exp Neurol. 2015 Sep;271:335-50. doi: 10.1016/j.expneurol.2015.05.021. Epub 2015 May 30.

PMID:
26037043
7.

Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.

Paquette MA, Martinez AA, Macheda T, Meshul CK, Johnson SW, Berger SP, Giuffrida A.

Eur J Neurosci. 2012 Nov;36(9):3224-34. doi: 10.1111/j.1460-9568.2012.08243.x. Epub 2012 Aug 3.

8.

Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.

Bishop C, Krolewski DM, Eskow KL, Barnum CJ, Dupre KB, Deak T, Walker PD.

J Neurosci Res. 2009 May 15;87(7):1645-58. doi: 10.1002/jnr.21978.

9.

Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.

Lindenbach D, Palumbo N, Ostock CY, Vilceus N, Conti MM, Bishop C.

Br J Pharmacol. 2015 Jan;172(1):119-30. doi: 10.1111/bph.12894. Epub 2014 Nov 24.

10.

The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.

Shin E, Lisci C, Tronci E, Fidalgo C, Stancampiano R, Björklund A, Carta M.

Neurobiol Dis. 2014 Feb;62:233-40. doi: 10.1016/j.nbd.2013.09.021. Epub 2013 Oct 14.

PMID:
24135006
11.

Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors.

Sagarduy A, Llorente J, Miguelez C, Morera-Herreras T, Ruiz-Ortega JA, Ugedo L.

Exp Neurol. 2016 Mar;277:35-45. doi: 10.1016/j.expneurol.2015.12.005. Epub 2015 Dec 11.

12.

Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.

Lindenbach D, Dupre KB, Eskow Jaunarajs KL, Ostock CY, Goldenberg AA, Bishop C.

Brain Res. 2013 Nov 6;1537:327-39. doi: 10.1016/j.brainres.2013.09.020. Epub 2013 Sep 21.

13.

The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.

McCreary AC, Varney MA, Newman-Tancredi A.

Neuropharmacology. 2016 Jun;105:651-660. doi: 10.1016/j.neuropharm.2016.01.013. Epub 2016 Jan 9.

PMID:
26777281
14.

The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.

Frau R, Savoia P, Fanni S, Fiorentini C, Fidalgo C, Tronci E, Stancampiano R, Meloni M, Cannas A, Marrosu F, Bortolato M, Devoto P, Missale C, Carta M.

Exp Neurol. 2017 May;291:1-7. doi: 10.1016/j.expneurol.2017.01.012. Epub 2017 Jan 26.

PMID:
28131725
15.

Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.

Kumar R, Riddle LR, Griffin SA, Chu W, Vangveravong S, Neisewander J, Mach RH, Luedtke RR.

Neuropharmacology. 2009 May-Jun;56(6-7):956-69. doi: 10.1016/j.neuropharm.2009.01.019. Epub 2009 Feb 5.

16.

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.

Brain. 2008 Dec;131(Pt 12):3380-94. doi: 10.1093/brain/awn235. Epub 2008 Oct 24.

PMID:
18952677
17.

Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Gerlach M, Bartoszyk GD, Riederer P, Dean O, van den Buuse M.

J Neural Transm (Vienna). 2011 Dec;118(12):1733-42. doi: 10.1007/s00702-010-0571-8. Epub 2011 Jan 21.

PMID:
21253782
18.

Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.

Iderberg H, Rylander D, Bimpisidis Z, Cenci MA.

Exp Neurol. 2013 Dec;250:116-24. doi: 10.1016/j.expneurol.2013.09.003. Epub 2013 Sep 10.

PMID:
24029003
19.

Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.

Shin E, Garcia J, Winkler C, Björklund A, Carta M.

Neurobiol Dis. 2012 Sep;47(3):393-406. doi: 10.1016/j.nbd.2012.03.038. Epub 2012 Apr 12.

PMID:
22579773
20.

Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.

Bézard E, Muñoz A, Tronci E, Pioli EY, Li Q, Porras G, Björklund A, Carta M.

Neurosci Res. 2013 Dec;77(4):242-6. doi: 10.1016/j.neures.2013.10.002. Epub 2013 Oct 14.

PMID:
24135129

Supplemental Content

Support Center